Loading organizations...
Truffle Capital is a European venture capital firm that builds and finances pioneering BioMedTech and deep tech for the financial sector. It operates as a business builder in life sciences and a lead investor in fintech and insurtech, offering hands-on development and strategic support to emerging enterprises.
Founded in 2001, Truffle Capital was established by Philippe Pouletty, M.D., Bernard-Louis Roques, and Chairman Henri Moulard. Dr. Pouletty, a serial entrepreneur and inventor, contributed life sciences expertise. Roques brought venture capital and trading experience, while Moulard offered executive leadership, combining diverse insights to foster advancements.
Truffle Capital partners with high-potential startups and scale-ups in BioMedTech and financial technology. Its mission drives the creation and development of enterprises destined to become future industry leaders. Active support guides its portfolio companies toward impactful market positions and sustained growth.
Key people at Truffle Capital.
Truffle Capital was founded in 2001 by Bernard-Louis Roques (Co-Founder and General Partner) and Philippe Pouletty (Co-Founder and General Director) and Henri Moulard (Co-Founder and President) and Dimitri Popov (Founder).
Truffle Capital is a leading independent European venture capital firm founded in 2001, specializing in financing and supporting pioneering technologies in life sciences (MedTech, Biotech, BioEcoTech) and deeptech applied to finance (Fintech and Insurtech).[1][2][4] Its mission is to drive the creation and development of innovative companies into tomorrow's leaders in healthcare and finance/insurance, acting as a lead investor with proactive governance, managing €500M in assets under management (AuM), having raised over €1.2Bn, and supporting 124 companies with 45 exits and 15 IPOs.[1][4] The firm's investment philosophy emphasizes deep sector expertise, strategic partnerships via its ecosystem (including LPs like banks and insurers), value-based investing for capital efficiency, and focus on proprietary AI, blockchain, cybersecurity, and deep tech spin-offs, targeting Series A to growth-stage companies with >€5M recurring revenue and €5-15M tickets.[1][3][4][5]
Truffle Capital significantly impacts the startup ecosystem by fostering collaborations that accelerate innovation and scaling—60% of Fintech portfolio companies benefit from partnerships or co-investments with its network—while providing operational support like recruitment, market analysis, and strategic planning.[1][4][5]
Truffle Capital was created in 2001 in Paris, France, by co-founders and CEOs Dr. Philippe Pouletty (a Ph.D. with extensive entrepreneurial and investment experience in Europe and North America) and Bernard-Louis Roques, who lead the firm alongside partners like Jean-François Fourt and Henri Moulard (per earlier profiles).[1][2][4] Pouletty chairs operations, drawing on decades of success in technology and healthcare deals.[4] The firm evolved from a broad focus on IT, life sciences, and energy/sustainable development to sharpening on disruptive deep tech in life sciences and Fintech/Insurtech since 2015, building an international team of experts and raising over €1.2Bn across funds.[1][2][3][5] Key milestones include supporting over 120 companies, achieving numerous exits, and pioneering Fintech investments with 23 deals and 7 exits in that vertical alone.[1][5]
Truffle Capital rides the wave of deep tech convergence in life sciences (e.g., MedTech/Biotech innovations addressing healthcare challenges) and Fintech/Insurtech (AI, blockchain, cybersecurity transforming financial institutions), where timing aligns with rising demand for scalable, regulatory-compliant solutions amid digital transformation and sustainability pushes.[1][3][5] Market forces like EU regulatory support for tech spin-offs, post-pandemic biotech acceleration, and Fintech's shift to embedded finance favor its thesis, especially as banks seek deep tech partners.[3][4][5] The firm influences the ecosystem by proactively curating partnerships, empowering 1,300+ portfolio employees across 16 active Fintech firms, and driving exits/IPOs that recycle capital into new leaders, solidifying Europe's VC presence against US/Asian dominance.[1][5]
Truffle Capital is poised to expand its €500M AuM through new funds targeting AI-driven Fintech and life sciences breakthroughs, capitalizing on EU deep tech momentum and its proven ecosystem for more exits and IPOs.[1][5] Trends like regulatory tailwinds for blockchain/cybersecurity in finance and bio-convergence in healthcare will shape its path, potentially evolving its influence toward larger growth equity plays and cross-sector synergies. As more than mere investors, Truffle's ecosystem-building DNA positions it to nurture Europe's next tech leaders in innovation financing.[1][4][5]
Truffle Capital was founded in 2001 by Bernard-Louis Roques (Co-Founder and General Partner) and Philippe Pouletty (Co-Founder and General Director) and Henri Moulard (Co-Founder and President) and Dimitri Popov (Founder).
Key people at Truffle Capital.
Truffle Capital has 6 tracked investments across 5 companies. The latest tracked deal is $6.0M Series A in Cachet in May 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2022 | Cachet | $6.0M Series A | Truffle Capital | Icebreaker.vc, Uniqa Ventures |
| Jun 16, 2015 | Actility | $25.3M Other Equity | Dominique Pitteloud | BPI Green Tech Investment, Idinvest Partners, Jasper Snijder, Pierre Louette, Jean Paul DE Weck |
| Sep 13, 2013 | CoolGames | $5.0M Series A | — | Neomobile, Solid Ventures |
| Feb 8, 2012 | CoolGames | $2.3M Other Equity | Solid Ventures, Truffle Capital | — |
| Jun 9, 2010 | Pharnext | $5.8M Series A | Truffle Capital | Charles Beigbeder, Claude Darmon, Olivier Fulconis, Aurinvest Capital 2, Financière Boscary |
| Mar 1, 2010 | Immune Targeting Systems | $13.0M Series A | — | Earlybird Venture Capital, HealthCap, London Technology Fund, Novartis |
